Norroy Bioscience Presents Promising Renal Cancer Imaging Data at 2025 ASCO Annual Meeting
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place in Chicago, USA, from May 30 to June 3, bringing together oncology professionals from around the world. At this global event, Norroy Bioscience presented, for the first time via poster, new clinical data on its novel renal cancer imaging agent, 68Ga-NYM005 (NY104), a first-in-class small molecule radiopharmaceutical targeting carbonic anhydrase IX (CAIX).
ASCO Abstract
Title: 68Ga-NYM005 (NY104) PET/CT and 18F-FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): a prospective, single-center, single-arm, comparative imaging trial
Abstract Number: 4524
Location: Chicago, USA
About the Study 68Ga-NYM005 (NY104), developed in-house by Norroy Bioscience, is a first-in-class CAIX-targeting PET tracer with high affinity and specificity. The agent has completed Phase I/II clinical studies and is expected to enter multi-center Phase III trials in the second half of 2025. Currently, there is no similar product approved globally.
In this prospective, single-arm imaging trial, 45 patients with metastatic clear cell renal cell carcinoma (ccRCC) underwent both 68Ga-NYM005 PET/CT and 18F-FDG PET/CT scans within one week. A total of 682 lesions across 175 anatomical regions were evaluated. Key Findings The results demonstrate that 68Ga-NYM005 (NY104) significantly outperformed 18F-FDG PET/CT in detecting metastatic lesions, both at the lesion and region levels.
Additionally, SUVmax values for 68Ga-NYM005 were significantly higher in ccRCC lesions compared to non-ccRCC lesions (12.4 ± 11.8 vs. 1.2 ± 0.9), whereas no such difference was observed for 18F-FDG (7.5 ± 10.7 vs. 6.7 ± 3.4). A comparison of tumor-to-background ratios (TBRs) further supported the superior imaging contrast of 68Ga-NYM005.
Future Direction
Norroy Bioscience will continue exploring the diagnostic potential of 68Ga-NYM005 PET in suspected ccRCC and primary renal tumors. Furthermore, a next-generation theranostic CAIX-targeted radiopharmaceutical with enhanced affinity is under development. Preliminary research has shown promising therapeutic efficacy.
About Clear Cell Renal Cell Carcinoma (ccRCC)
ccRCC is the most common subtype of renal cancer, accounting for approximately 80–85% of all cases. Around 30% of patients present with distant metastases at initial diagnosis, and the 5-year survival rate for metastatic RCC remains below 5%. Conventional imaging lacks high-specificity molecular probes for ccRCC. 68Ga-NYM005 (NY104) offers a non-invasive, precise, and highly specific molecular imaging solution, and represents a new paradigm in ccRCC diagnosis. Norroy Bioscience is committed to advancing its integrated diagnostic and therapeutic nuclear medicine pipeline to bring new hope to patients worldwide.
